Summary: Back to ISER - The work of Experimentica's scientists at the forefront of Ophthalmology research will be featured at the XXV biennial meeting of the International Society of Eye Research.
The mission of ISER is to provide a unique international platform for discussion and exchange of ideas on contemporary topics in eye and vision research among its members and the broader eye and vision research community.
Presented by Experimentica Ltd.
Do not miss out on our team’s abstracts in physiopathology and preclinical model development.
A B S T R A C T
Algorithm development for angiogenesis quantification in the mouse oxygen-induced retinopathy model
5:30 PM – 7:00 PM AEST, February 20, 2023 | Poster #11
Authors: Vähätupa M, Kvietkauskiene N, Bijeikis S, Jarutis J, Jääskeläinen N, Jokinen V, Tenhunen A, Lappeteläinen B, Vergun O, Haapaniemi A, Kalesnykas G, Kaja S, Cerrada-Gimenez M
Purpose: The mouse model of oxygen-induced retinopathy (OIR) is a widely used model to study angiogenic responses in retinopathies. Avascular (AVA) and neovascular (NV) areas can be measured from the retinal flat mounts where the vasculature is labelled with Isolectin B4. Manual quantification of AVA and NV areas is time consuming and may lead to subjective bias. The aim of this study was to develop and validate an automated method for fast and unbiased quantification.
A B S T R A C T
Preclinical evaluation of lubricin/PRG4 for the treatment of allergic conjunctivitis
9:12 AM – 9:24 AM AEST, February 20, 2023
Authors: Iqbal S, De Alba M, Sagalov A, Pappenhagen N, Rao V, Fareed J, Bacellar-Galdino M, Kaja S
Purpose: Allergic conjunctivitis (AC) is associated with redness and swelling of the conjunctiva, increased lacrimation, and severe itching. Management includes lubricants, topical corticosteroids, NSAIDs, and anti-histamines. Limited efficacy and drug-induced adverse reactions call for novel safer and more efficacious treatments. Lubricin/proteoglycan 4 (PRG4) is an endogenous glycoprotein. Originally identified as a natural lubricant in synovial joints, PRG4 has recently emerged as a key natural molecule in the lubrication of the ocular surface. Recombinant PRG4 is currently in clinical trials for the treatment of dry eye disease. The objective of this study was to investigate the anti-inflammatory and anti-allergic properties of PRG4.
A B S T R A C T
Comparison of the streptozotocin-induced diabetic retinopathy model in Brown Norway and Sprague Dawley rats
5:30 PM – 7:00 PM AEST, February 21, 2023 | Poster #155
Authors: Cerrada-Gimenez M, Jääskeläinen N, Tähtivaara L, Thapa R, Tenhunen A, Nevalainen T, Haapaniemi A, Jokinen V, Miller C, Vähätupa M, Kvietkauskiene N, Bijeikis S, Jarutis J, Koskenniemi H, Kalesnykas G, Kaja S
Purpose: The streptozotocin (STZ)-induced diabetes rodent model is one of the most widely used preclinical models for diabetic retinopathy (DR).Most of the available literature has focused on the use of Sprague Dawley (SD) rats and very little is published with Brown Norway (BN) rats. In the current study we compared the development of DR in the two rat strains on a short-term study (12 weeks) with special focus on in vivo readouts.
A B S T R A C T
Role of lysyl oxidase like-1 in reactive astrocytosis
9:36 AM – 10:00 AM AEST, February 20, 2023
Authors: Kaja S, Hariani H, Kalesnykas G, Ghosh A, Jones WK, Rao V
Purpose: The extracellular matrix of the optic nerve head contains highly organized collagen and elastin fibers, making the optic nerve head a biomechanically-compliant tissue that readily adapts to diurnal fluctuations of intraocular pressure and changes in the translaminar pressure gradient. In glaucoma, including primary open angle glaucoma, extensive tissue remodeling at the optic nerve head leading to tissue stiffening is generally attributed to reactive astrocytosis of optic nerve head astrocytes (ONHA). The purpose of this study was to determine the role of lysyl oxidase like-1 (LOXL1), a critical enzyme required for elastin biogenesis and collagen cross-linking, in reactive astrocytosis in ONHA.
Meet with us in Gold Coast, Australia
Whether you have a question about our science, preclinical models, capabilities, pricing or anything else, our senior management and business development team is ready to answer your inquiries.
Simon Kaja, PhD
Chief Scientific Officer, VP Americas
Dr. Kaja is an internationally recognized expert in experimental ophthalmology and neuroscience and a regular consultant to both pharma and biotech companies. He has published over 50 peer-reviewed articles and book chapters. For more info visit Simon’s profile page or LinkedIn.
Maria Vähätupa, PhD
Director In Vivo Pharmacology
Dr. Vähätupa holds a Ph.D. degree in Biomedicine from Tampere University, Finland. She joined Experimentica Ltd. as a project researcher in angiogenesis-related studies in 2015. Dr. Vähätupa has a track-record of peer-reviewed publications in the field of pathologic angiogenesis in retina, vascular permeability and carcinogenesis. For more info visit Maria’s profile page or LinkedIn.
Marc Cerrada-Gimenez, PhD
Director of R&D Implementation
Dr. Cerrada-Gimenez obtained his PhD in Biotechnology from the A.I. Virtanen Institute at the University of Eastern Finland in 2011. Dr. Cerrada-Gimenez led the Biomarker and in vitro team designing and leading multiple projects at Charles River Discovery Services (Kuopio, Finland), then joined the biotech Minoryx Therapeutics as Head of Biomarker Discovery before joining Experimentica. For more info visit Marc’s profile page or LinkedIn.